RU2017139870A3 - - Google Patents

Download PDF

Info

Publication number
RU2017139870A3
RU2017139870A3 RU2017139870A RU2017139870A RU2017139870A3 RU 2017139870 A3 RU2017139870 A3 RU 2017139870A3 RU 2017139870 A RU2017139870 A RU 2017139870A RU 2017139870 A RU2017139870 A RU 2017139870A RU 2017139870 A3 RU2017139870 A3 RU 2017139870A3
Authority
RU
Russia
Application number
RU2017139870A
Other languages
Russian (ru)
Other versions
RU2017139870A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017139870(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2017139870A3 publication Critical patent/RU2017139870A3/ru
Publication of RU2017139870A publication Critical patent/RU2017139870A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2242Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2017139870A 2009-09-25 2017-11-16 Новые агонисты npr-b RU2017139870A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015124607A Division RU2636738C2 (ru) 2009-09-25 2010-09-23 Новые агонисты npr-b

Publications (2)

Publication Number Publication Date
RU2017139870A3 true RU2017139870A3 (enExample) 2019-05-16
RU2017139870A RU2017139870A (ru) 2019-05-16

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2012116531/04A RU2557290C2 (ru) 2009-09-25 2010-09-23 Новые агонисты npr-b
RU2015124607A RU2636738C2 (ru) 2009-09-25 2010-09-23 Новые агонисты npr-b
RU2017139870A RU2017139870A (ru) 2009-09-25 2017-11-16 Новые агонисты npr-b

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2012116531/04A RU2557290C2 (ru) 2009-09-25 2010-09-23 Новые агонисты npr-b
RU2015124607A RU2636738C2 (ru) 2009-09-25 2010-09-23 Новые агонисты npr-b

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR101768661B1 (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX354005B (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2557290C2 (enExample)
TW (2) TWI625126B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
KR101768661B1 (ko) 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 npr-b 길항제
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
US20150045301A1 (en) * 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
JP2020505476A (ja) * 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019379808C1 (en) * 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CA3184145A1 (en) * 2020-06-12 2021-12-16 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006005140A2 (en) * 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
BRPI0709427A2 (pt) 2006-03-30 2011-07-12 Palatin Technologies Inc "construto cìclico, composição farmacêutica e uso de um composto
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
KR101768661B1 (ko) * 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 npr-b 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Also Published As

Publication number Publication date
ZA201702958B (en) 2018-08-29
KR20170094564A (ko) 2017-08-18
TWI625126B (zh) 2018-06-01
US9982016B2 (en) 2018-05-29
US20130345394A1 (en) 2013-12-26
PH12012500562A1 (en) 2012-10-22
US20180334477A1 (en) 2018-11-22
AU2010298256A1 (en) 2012-04-12
TWI577384B (zh) 2017-04-11
MX2012003398A (es) 2012-04-10
RU2636738C2 (ru) 2017-11-28
CN105732767A (zh) 2016-07-06
US20160194357A1 (en) 2016-07-07
CA2773949A1 (en) 2011-03-31
KR101854820B1 (ko) 2018-05-04
EP2480247B1 (en) 2020-02-12
RU2557290C2 (ru) 2015-07-20
JP2017137362A (ja) 2017-08-10
MX370645B (es) 2019-12-19
AU2010298256B2 (en) 2015-08-13
US8546523B2 (en) 2013-10-01
WO2011038061A2 (en) 2011-03-31
KR20120091110A (ko) 2012-08-17
KR20180049198A (ko) 2018-05-10
AR078445A1 (es) 2011-11-09
JP5893561B2 (ja) 2016-03-23
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
US20170313743A1 (en) 2017-11-02
TW201630619A (zh) 2016-09-01
ZA201201630B (en) 2014-05-28
US20110077381A1 (en) 2011-03-31
UY32902A (es) 2011-02-28
RU2015124607A (ru) 2015-12-10
EP2480247A2 (en) 2012-08-01
JP6211032B2 (ja) 2017-10-11
CA2773949C (en) 2020-11-03
US9745344B2 (en) 2017-08-29
CN102548574A (zh) 2012-07-04
ZA201401625B (en) 2018-08-25
EP2480247A4 (en) 2013-09-04
US10196423B2 (en) 2019-02-05
TW201110974A (en) 2011-04-01
MX354005B (es) 2018-02-08
BR112012006579A2 (pt) 2016-11-22
WO2011038061A3 (en) 2011-07-28
RU2017139870A (ru) 2019-05-16
RU2012116531A (ru) 2013-10-27
CL2017001190A1 (es) 2017-12-01
JP2015131856A (ja) 2015-07-23
CN102548574B (zh) 2016-03-23
KR101768661B1 (ko) 2017-08-16
JP2013505937A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
BE2015C040I2 (enExample)
BRPI0925311A2 (enExample)
BR112012008195A2 (enExample)
BR112012003062A2 (enExample)
BRPI0924307A2 (enExample)
BR112012008267A2 (enExample)
BR112012000607A2 (enExample)
BR122021004633A2 (enExample)
BR112012000665A2 (enExample)
BR112012012487A2 (enExample)
BR112012003080A2 (enExample)
BR122017024704A2 (enExample)
BR112012003853A2 (enExample)
BR112012009797A2 (enExample)
BR112012012080A2 (enExample)
BR112012009446A2 (enExample)
BR112012009703A2 (enExample)
BRPI0924534A2 (enExample)
BR112012010357A2 (enExample)
BR112012007656A2 (enExample)
BR122019005883A2 (enExample)
BR112012001263A2 (enExample)
BR112012014856A2 (enExample)
BR112012000159A2 (enExample)
BRPI1004942A2 (enExample)